Eisai launches cancer drug Halaven in UK
April 20, 2011Sales and Marketing Eisai, Halaven, breast cancer
Eisai’s sea sponge derived breast cancer drug Halaven has been launched in the UK following approval from European regulators a …
Novavax appoints Stanley Erck chief executive
April 20, 2011Research and Development appointment, research and development
US biopharmaceutical company Novavax has reorganised its senior management. The changes see former executive chairman Stanley Erck take on the …
Generics push US drug growth to $307bn
April 20, 2011IMS, IMS Health, drug spending, healthcare spending
Generics replaced branded drugs as the main growth drivers for the US pharmaceutical market in 2010. The market saw just …
Warner Chilcott plans to axe 500 jobs in Europe
April 20, 2011Manufacturing and Production, Research and Development, Sales and Marketing Warner Chilcott, pharma job cuts
Warner Chilcott is looking to cut 500 jobs from its European operations as it seeks to minimise the impact of …
Contract research news in brief
April 20, 2011Research and Development CRO, contract research
Our contract research news round-up features updates from BioClinica, Vyteris, CROMSOURCE, Quintiles, Imperial/D. Anderson and PRA International. Clinical trial management …
Life Healthcare Communications expands
April 20, 2011Medical Communications appointment, medical communications
Life Healthcare Communications has expanded, adding new employees and extending its existing digital department.The Berkshire, UK-based creative communications agency has …
Circassia raises funds to develop allergy products
April 19, 2011Research and Development Circassia, UK biotech, biotech
UK biopharma company Circassia has raised £60 million funding for the final stage of development of its anti-allergy products. The …
Oral MS drug Gilenya launched in the UK
April 19, 2011Sales and Marketing Novartis, gilenya, multiple sclerosis
Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …
NICE unimpressed with Novartis’ patient access scheme
April 19, 2011Sales and Marketing Afinitor, Kidney cancer, NICE, Novartis
Novartis has been dealt a blow by NICE after the cost-effectiveness body finally refused to recommend, on appeal, its kidney …
FDA issues guidance on preventing antibiotic cross-contamination
April 19, 2011Manufacturing and Production FDA, GMP, pharma manufacturing
The FDA has published a new guidance document to help drugmakers prevent cross-contamination of pharmaceuticals with non-penicillin beta-lactam antibiotics. The …
Organogenesis to build ‘largest automated living cell facility’
April 19, 2011Manufacturing and Production Cell biology, Organogenesis, pharma manufacturing
Regenerative medicine specialist Organogenesis has started construction of an automated manufacturing facility for human cells, which it claims will be …
J&J and Merck reach compromise on arthritis drug rights
April 19, 2011Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi
Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …
GlaxoSmithKline OTC sale puts two plants on the block
April 19, 2011Manufacturing and Production GSK, US, pharma manufacturing
GlaxoSmithKline’s decision to sell off a swathe of over-the-counter medicines means that a manufacturing facility in Memphis, Tennessee, has been …
Boehringer’s Pradaxa recommended for expanded European licence
April 18, 2011Sales and Marketing Boehringer Ingelheim, CHMP, Pradaxa
Pradaxa is on course to expand its European licence with a recommendation from the CHMP for a new indication in …
Tim Mustill and Jenny Hepburn join InterPhase
April 18, 2011Sales and Marketing appointment, sales and marketing
KnowledgePoint360 Group has appointed Tim Mustill and Jennifer Hepburn to key positions within its strategic consulting practice InterPhase. Tim has …
Phase III boost for Pfizer’s oral arthritis drug
April 18, 2011Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib
Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …
TBA contamination prompts Topamax recall
April 18, 2011Manufacturing and Production Johnson and Johnson, recalls
Another Johnson & Johnson business unit has decided to recall medicines because of a mouldy smell thought to be caused …
VBP: a fait accompli or room for manoeuvre?
April 18, 2011Sales and Marketing value-based pricing
The pharma industry is seeking a compromise on the UK’s proposed value- based pricing, which promises to revolutionise the country’s …
Genzyme MS drug shines in head-to-head trial with Rebif
April 18, 2011Research and Development, Sales and Marketing Genzyme, Lemtrada, Sanofi-Aventis, relapsing multiple sclerosis
Genzyme’s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial. Five years’ worth of mid-stage data …
Fishawack gains industry experts
April 15, 2011Medical Communications Fishawhack, PR
The Fishawack Group has gained industry experts Linda Harris and Jo Jarvis to expand its stakeholder relations and thought leader …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
